PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC

NCT03829007 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer

Interventions

DIAGNOSTIC_TEST: PD-L1 imaging
DRUG: Durvalumab

Sponsor

Radboud University Medical Center

Collaborators

[object Object]